Semin Thromb Hemost 2020; 46(07): 823-825
DOI: 10.1055/s-0040-1710006

Platelets in Coronavirus Disease 2019

Julie Brogaard Larsen
1   Thrombosis and Haemostasis Research Unit, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
Leonardo Pasalic
2   Sydney Centres for Thrombosis and Haemostasis, Sydney, Australia
3   Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, NSW Health Pathology, Sydney, Australia
Anne-Mette Hvas
1   Thrombosis and Haemostasis Research Unit, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
4   Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
› Author Affiliations

In December 2019, the first cases of infection with a novel human microorganism, now officially defined as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were reported in Wuhan, China.[1] On April 1, 2020, as we write, more than 800,000 cases of the novel coronavirus disease 2019 (COVID-19) have been reported worldwide, with more than 40,000 COVID-19–related deaths.[2]

Studies have reported disturbed coagulation in COVID-19 patients, including prolonged prothrombin time,[3] [4] decreased antithrombin,[3] and increased fibrin degradation products such as D-dimer.[3] [4] [5] [6] [7] This implies increased risk of thromboembolic disease, as well as bleeding and, for the most serious cases, development of disseminated intravascular coagulation (DIC), which, in one case series, was reported in as many as 71% of nonsurvivors of COVID-19.[5]

This commentary explores the potential role of platelets in COVID-19, including the link between thrombocytopenia and disease severity and the considerations for the potential role for platelet function and/or platelet activation testing in COVID-19 patients.

Publication History

Article published online:
30 April 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

  • References

  • 1 Zhu N, Zhang D, Wang W. et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382 (08) 727-733
  • 2 John's Hopkins University. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available at: . Accessed April 1, 2020
  • 3 Han H, Yang L, Liu R. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020; (e-pub ahead of print) DOI: 10.1515/cclm-2020-0188.
  • 4 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062
  • 5 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (04) 844-847
  • 6 Guan WJ, Ni ZY, Hu Y. et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; (e-pub ahead of print) DOI: 10.1056/NEJMoa2002032.
  • 7 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
  • 8 Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223): 507-513
  • 9 Fan BE, Chong VCL, Chan SSW. et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol 2020
  • 10 Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 2020; 506: 145-148
  • 11 Mo P, Xing Y, Xiao Y. et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 2020; (e-pub ahead of print) DOI: 10.1093/cid/ciaa270.
  • 12 Wang D, Yin Y, Hu C. et al. Clinical course and outcome of novel coronavirus COVID-19 infection in 107 patients discharged from the Wuhan hospital. Crit Care 2020; (e-pub ahead of print) DOI: 10.21203/
  • 13 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; (e-pub ahead of print) DOI: 10.1111/jth.14817.
  • 14 Xu XW, Wu XX, Jiang XG. et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368: m606
  • 15 Liu W, Tao ZW, Lei W. et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) 2020; (e-pub ahead of print) DOI: 10.1097/CM9.0000000000000775.
  • 16 Young BE, Ong SWX, Kalimuddin S. et al; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020; (e-pub ahead of print) DOI: 10.1001/jama.2020.3204.
  • 17 Yang X, Yu Y, Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; (e-pub ahead of print) DOI: 10.1016/S2213-2600(20)30079-5.
  • 18 Arentz M, Yim E, Klaff L. et al. Characteristics and outcomes of 21 critically ill patients With COVID-19 in Washington state. JAMA 2020; (e-pub ahead of print) DOI: 10.1001/jama.2020.4326.
  • 19 Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; (e-pub ahead of print) DOI: 10.1007/s00134-020-05991-x.
  • 20 Bhatraju PK, Ghassemieh BJ, Nichols M. et al. COVID-19 in critically ill patients in the Seattle region - case series. N Engl J Med 2020; (e-pub ahead of print) DOI: 10.1056/NEJMoa2004500.
  • 21 Qu R, Ling Y, Zhang YH. et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol 2020; (e-pub ahead of print) DOI: 10.1002/jmv.25767.
  • 22 Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection. Semin Thromb Hemost 2020; 46 (03) 302-319
  • 23 Choi KW, Chau TN, Tsang O. et al; Princess Margaret Hospital SARS Study Group. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med 2003; 139 (09) 715-723
  • 24 Wong RS, Wu A, To KF. et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 2003; 326 (7403): 1358-1362
  • 25 Saad M, Omrani AS, Baig K. et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 2014; 29: 301-306
  • 26 Assiri A, Al-Tawfiq JA, Al-Rabeeah AA. et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13 (09) 752-761
  • 27 Yang M, Ng MH, Li CK. Thrombocytopenia in patients with severe acute respiratory syndrome (review). Hematology 2005; 10 (02) 101-105
  • 28 Qin C, Zhou L, Hu Z. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020; (e-pub ahead of print) DOI: 10.1093/cid/ciaa248.
  • 29 Gao Y, Li T, Han M. et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020; (e-pub ahead of print) DOI: 10.1002/jmv.25770.
  • 30 Oleksowicz L, Mrowiec Z, Zuckerman D, Isaacs R, Dutcher J, Puszkin E. Platelet activation induced by interleukin-6: evidence for a mechanism involving arachidonic acid metabolism. Thromb Haemost 1994; 72 (02) 302-308